Speciality Medicines Ltd Reports Strong FY26 Performance

Speciality Medicines Limited has announced robust financial results for the fiscal year ended March 31, 2026. Net profit surged by 81.01% to ₹13.03 crore, while revenue from operations increased by 29.21% to ₹75.29 crore compared to the previous fiscal year.

Reader Takeaway: Strong profit growth and significant IPO funds available for future expansion, but tax benefit sustainability is a watchpoint.

What just happened

Speciality Medicines Limited reported its audited financial results for FY2026. The company posted a net profit of ₹13.03 crore, an 81.01% increase from ₹7.20 crore in FY2025. Revenue from operations grew by 29.21% year-on-year to ₹75.29 crore. Earnings per share (EPS) also saw a significant jump of 70.57% to ₹20.11 from ₹11.79.

The company also provided an update on its Initial Public Offering (IPO) fund utilization. As of March 31, 2026, Speciality Medicines had utilized ₹5.09 crore out of the ₹29.14 crore raised. The remaining ₹24.05 crore is earmarked for research and development (R&D) centre setup, product registration, and working capital.

The audit report for these financials carried an unmodified opinion.

Why this matters

The substantial increase in net profit, outpacing revenue growth, suggests improved operational efficiencies and margin expansion for Speciality Medicines. The healthy unutilized IPO fund balance provides significant financial flexibility for future growth initiatives, particularly in R&D and market expansion.

The backstory

Speciality Medicines Limited is a pharmaceutical company focused on developing and marketing specialized medicinal products. The company recently concluded its IPO to raise capital for its expansion plans.

What changes now

Investors can expect the company to focus on deploying the remaining IPO funds for its stated growth objectives. The strong financial performance provides a positive backdrop for these expansion activities.

Risks to watch

Speciality Medicines currently benefits from a tax deduction under Section 80-IAC due to its start-up recognition. The company's tax provisions are based on Minimum Alternate Tax (MAT). Any change or loss in this start-up recognition could lead to higher future tax liabilities, impacting net profitability.

Peer comparison

(No peer comparison data available in the filing)

Context metrics (time-bound)

• Revenue Growth (FY26 vs FY25): +29.21%
• Net Profit Growth (FY26 vs FY25): +81.01%
• IPO Funds Raised: ₹29.14 crore
• IPO Funds Utilized (as of Mar 31, 2026): ₹5.09 crore
• IPO Funds Unutilized (as of Mar 31, 2026): ₹24.05 crore

What to track next

Investors should monitor the company's progress in setting up the R&D center, obtaining product registrations, and the effective utilization of the remaining IPO funds. Additionally, keeping track of any regulatory changes impacting the company's tax benefits will be crucial.